Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
1.365
USD
-3.19%
-12.50%
-48.30%
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000E Index
June 23, 2023 at 12:00 am EDT
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000E Index
Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024
Apr. 08
North American Morning Briefing : Inflation Data, -2-
Apr. 08
DJ
Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 28
CI
North American Morning Briefing : Tech in Focus on -2-
Mar. 25
DJ
North American Morning Briefing : Investors -2-
Mar. 18
DJ
Jefferies Starts Cue Biopharma With Buy Rating
Mar. 13
MT
Transcript : Cue Biopharma, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Nov. 09
Piper Sandler Adjusts Price Target on Cue Biopharma to $8 From $7, Maintains Overweight Rating
Nov. 06
MT
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 03
CI
Cue Biopharma Reports Prolonged Survival in Phase 1 Trials of CUE-101; Shares Climb
Nov. 03
MT
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023
Nov. 03
CI
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?
23-09-26
CI
Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023
23-09-14
CI
Transcript : Cue Biopharma, Inc., Q2 2023 Earnings Call, Aug 09, 2023
23-08-09
Cue Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-08
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000 Index
23-06-23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000E Growth Index
23-06-23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000E Index
23-06-23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell Small Cap Completeness Index
23-06-23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2000 Growth Index
23-06-23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2500 Index
23-06-23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2000 Index
23-06-23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 3000 Growth Index
23-06-23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2000 Dynamic Index
23-06-23
CI
Cue Biopharma, Inc.(NasdaqCM:CUE) added to Russell 2500 Growth Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
More about the company
Last Close Price
1.365
USD
Average target price
9.4
USD
Spread / Average Target
+588.64%
Consensus
1st Jan change
Capi.
-48.30% 66.4M -2.31% 103B +0.56% 95.28B +1.69% 22.15B -17.37% 21.02B -9.30% 18.15B -41.01% 16.74B -14.85% 16.05B +3.21% 13.68B +33.54% 12.17B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
CUE BIOPHARMA, INC. 
